Physician profile
Ani Baroni
NPI 1487826871
$2,343.57
in general payments reported to CMS, 2019-2025
14 companies · $1,413 in 2025
The $1,413 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $714 · 2024: $216 · 2025: $1,413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,343.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $543.14 | 2023-2025 | Kxl System (Not Refurbished), Kxl1b-Ce-Marked Kxlsystem, Photrexa Viscous and Photrexa |
| Tarsus Pharmaceuticals, INC. | $389.87 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $316.55 | 2025 | Clareon Panoptix Pro, Centurion, Dailies Total1 |
| Bausch & Lomb Americas INC. | $243.42 | 2025 | Xiidra, Miebo |
| Johnson & Johnson Vision Care, INC. | $180.44 | 2024-2025 | Acuvue |
| Lumenis Be INC | $140.00 | 2023 | M22 |
| Sun Pharmaceutical Industries INC. | $125.00 | 2025 | |
| Oyster Point Pharma, INC. | $120.16 | 2023 | Tyrvaya |
| Astellas Pharma US INC | $119.83 | 2024 | Izervay |
| Coopervision INC. | $49.28 | 2023-2025 | Myday Contact Lens, Misight Contact Lens |
| Novartis Pharmaceuticals Corporation | $48.60 | 2023 | |
| Harrow Eye, LLC | $35.70 | 2025 | Vevye |
| Sight Sciences, INC. | $18.09 | 2023 | Tearcare System |
| Biotissue Holdings INC. | $13.49 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ani Baroni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.